The effects of treatment of anemia with exogenous recombinant erythropoietin (EPO) beta and iron on levels of antibodies against oxidized low-density lipoproteins as well as on serum PON1 activity and concentration were studied in 49 predialysis patients with chronic renal disease [45]. Here, PON1 is linked to chronic renal failure syndrome.